Baroreflex stimulation in antihypertensive treatment

Current Hypertension Reports

Volumn 12, Issue 3, 2010, Pages 176-181

  Taylor, Jeremy G ^a   Bisognano, John D ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Baroreflex; Carotid sinus stimulation; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BAROREFLEX STIMULATION THERAPY; BLOOD PRESSURE REGULATION; CAROTID SINUS MASSAGE; CAROTID SINUS PRESSORECEPTOR REFLEX; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE RESISTANCE; HEART FAILURE; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; MEDICAL INSTRUMENTATION; MORBIDITY; MORTALITY; NONHUMAN; PARASYMPATHETIC TONE; PATIENT SAFETY; REVIEW; SYMPATHETIC TONE;

ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; CAROTID SINUS; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; SYMPATHETIC NERVOUS SYSTEM;

EID: 77956383571     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0106-6     Document Type: Review

References (45)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003, 289:2362-2369.
2. Rosamond W, Flegal K, Furie K, et al.: Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e76-e80.
3. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al.: Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 2008,336:1121-1123.
4. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
5. World Health Organization: World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization, 2002.
6. Ong KL, Cheung BM, Man YB, et al.: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49:69-75.
7. Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in 5 European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
8. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
9. Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
10. Filippone JD, Bisognano JD: Baroreflex stimulation in the treatment of hypertension. Curr Opin Nephrol Hypertens 2007, 16:403-408. This article provides a good background on the history and development of baroreflex-stimulating technology.
11. Braunwald E, Zipes D, Lippy P: Heart Disease, A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders; 2001:2173.
12. Lohmeier TE, Hildebrandt DA, Warren S, et al.: Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol 2005, 288:R828-R836.
13. Chapleau MW: Arterial baroreflexes. In Hypertension Primer: The Essentials of High Blood Pressure, edn 4. Edited by Izzo JL, Black H.R. Philadelphia: Lippincott Williams & Wilkins; 2007:120-122. This book chapter provides a detailed discussion about baroreflex physiology, particularly its effects on the neurohormonal system.
14. Rooke T, Sparks H Jr: Control mechanisms in circulatory function. In Medical Physiology, edn 2. Edited by Rhoades RA, Tanner G.A. London: Lippincott Williams & Wilkins; 2003:290-303.
15. McCubbin JW, Green JH, Page IH: Baroreceptor function in chronic renal hypertension. Circ Res 1956, 4:205-210.
16. Carlsten A, Folkow B, Grimby G, et al.: Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol Scand 1958, 44:138-145.
17. Bristow JD, Honour AJ, Pickering GW, et al.: Diminished baroreflex sensitivity in high blood pressure. Circulation 1969, 39:48-54.
18. Warner HR: The frequency-dependent nature of blood pressure regulation by the carotid sinus studies with an electrical analog. Circ Res 1958, 6:35-40.
19. Bilgutay A, Lillehei W: Treatment of hypertension with an implantable electronic device. JAMA 1965, 191:649-653.
20. Bilgutay A, Lillehei W: Surgical treatment of hypertension with reference to baropacing. Am J Cardiol 1966, 17:663-667.
21. Schwartz S, Griffith L, Neistadt A, Hagfors N: Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg 1967, 114:5-15.
22. Tuckman J, Reichman T, Lyon A, et al.: Electrical stimulation of the sinus nerves in hypertensive patients: clinical evaluation and physiological studies. Hypertension 1967, 194S:23-28.
23. Lohmeier TE, Lohmeier JR, Haque A, Hildebrandt DA: Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol 2000, 279 (4):R1437-R1448.
24. Lohmeier TE, Irwin E, Rossing M, et al.: Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004, 43:306-311.
25. Barrett CJ, Guild SJ, Ramchandra R, Maplas SC: Baroreceptor denervation prevents sympathoinhibition during angiotensin IIinduced hypertension. Hypertension 2005, 46:1-5.
26. Lohmeier TE, Dwyer TM, Irwin ED, et al.: Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007, 49:1307-1314.
27. Lohmeier TE, Hildebrandt DA, Dwyer TM: Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 2007, 49:373-379.
28. Uppuluri SC, Storozynsky E, Bisognano JD: Baroreflex device therapy in the treatment of hypertension. Curr Hypertens Rep 2009, 11:69-75.
29. Lohmeier TE, Barrett AM, Irwin ED: Prolonged activation of the baroreflex: a viable approach for the treatment of hypertension? Curr Hypertens Rep 2005, 7:193-198.
30. Tordoir JHM, Scheffers I, Schmidli J, et al.: An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multicenter feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 2007, 33:414-421.
31. Illig KA, Levy M, Sanchez L, et al.: An implantable carotid sinus stimulator for drug resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos Feasibility Trial. J Vasc Surg 2006, 44:1213-1218.
32. Bisognano J, Sloand J, Papademetriou V, et al.: An implantable carotid sinus baroreflex activating system for drug-resistant hypertension: interim chronic efficacy results from the multicenter Rheos Feasibility Trial. Circulation 2006, 114(18 Suppl):II575.
33. Scheffers I, Schmidli J, Kroon AA, et al.: Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 2-year data from the Rheos DEBuT-HT study in patients with resistant hypertension. J Hypertens 2008, 26(Suppl I):S19.
34. Scheffers I, Schmidli J, Kroon AA, et al.: Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 3-year data from the Rheos DEBuT study in patients with resistant hypertension. J Hypertens 2009, 27 (Suppl 4):S421.
35. Rothstein M, de Leeuw P, Elletson M; The DEBuT and Rheos Feasibility Investigators: Chronic treatment of resistant hypertension with an implantable device: interim 2 year results of two studies of the Rheos hypertension system [abstract]. Presented at the American College of Cardiology 58th Annual Scientific Session. Orlando, FL; March 29-31, 2009.
36. Sica DA: Baroreflex activation in drug-resistant hypertension. US Cardiol 2009, 5(I):29-32.
37. Young K, Teeters J, Benesch C, et al.: Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J Clin Hypertens 2009, 11:555-563.
38. Textor SC: What price for blood pressure control? J Clin Hypertens 2009, 11:537-539.
39. Sabbah HN, Imai M, Irwin E, et al.: Chronic electrical activation of the carotid baroreflex improves left ventricular systolic and diastolic function in dogs with advanced heart failure [abstract]. Circulation 2005, 112(17):557.
40. Zucker IH, Hackley JF, Cornish KG, et al.: Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007, 50:904-910.
41. Gupta RC, Mishra S, Irwin ED, et al.: Chronic reflex activation therapy normalized gene expression of nitric oxide synthetase in left ventricular myocardium of dogs with chronic heart failure [abstract]. J Am Coll Cardiol 2007, 49(Suppl 9):86.A.
42. Bisognano JD, De Leeuw P, Bach DS, et al.: Improved functional capacity and cardiovascular structure after baroreflex activation therapy in resistant hypertension patients with symptomatic heart failure : Results from European and United States trials of Rheos® System. J Card Failure 2009, 15(6):S63.
43. de Leeuw P, Bisognano JD, Bach BS, et al.: Improved myocardial energetics following chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of Rheos® System. Circulation 2009, 120: S1005.
44. Bisognano J, de Leeuw P, Irwin E, et al. : Reduced arrhythmia burden in a resistant hypertensive patient receiving baroreflex activation therapy from an implantable device. Heart Rhythm 2009, 6(5):S327.
45. CVRx, Inc. Available at http://www.cvrx.com/medpros/index. php?id=16&parentid=16. Accessed November 2009. This website provides detailed and up-to-date information on the BHT system, with links to key publications.